iThera’s MSOT technology (multispectral optoacoustic tomography) has the unique capability of visualizing optical contrast at high resolution in deep tissue and displaying the image in real time. It is already in use for preclinical and clinical research around the globe and is currently being developed for diagnostic applications. Results from a…
Up to now the USA, with its impressive number of academic spin-offs, has been held up as a shining example in the German start-up landscape. A recently published analysis in Nature Biotechnology now shows a more nuanced picture: around 40% of US biotech start-ups have never really got off the ground, i.e. they have acquired no more than one…
For over 15 years, Prof. Thomas Blankenstein and his teams at the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association and at the Berlin Charité have been pursuing the goal of using T cells in cancer therapy. Their vision is a promising one, as T cells are particularly effective ‘killer cells’ of the immune system.
T…
Teams led by Prof. Joachim Hauber at the Heinrich Pette Institute (HPI) – Leibniz Institute for Experimental Virology and Prof. Frank Buchholz* at the Technische Universität Dresden have developed a completely new approach to the therapy of HIV-1 infection. With the help of the designer recombinase Brec1 – which acts like a pair of ‘molecular…
Dr Thomas Aper, Prof. Mathias Wilhelmi and their team at the Department of Cardiothoracic, Transplant and Vascular Surgery (Director: Prof. Axel Haverich) at the Hannover Medical School (MHH) have developed a new approach to producing natural vascular prostheses. Using a highspeed rotation method, the blood clotting protein fibrin is first…
Poseida, Demeetra and Hera BioLabs have recently launched a new tool for the targeted alteration of genes that offers an attractive alternative to the widely used CRISPR-Cas9 method. Their system, Cas-CLOVER™, employs the endonuclease Clo51, discovered and characterized by Dr Ralf Kühn* at the Institute of Developmental Genetics of the Helmholtz…
We are observing two trends in the start-up scene that encourage us and concern us, respectively. On the one hand, start-ups are gaining momentum and are now on par with licensing - as a vehicle for technology transfer and a source of proceeds. On the other hand, it is becoming increasingly difficult to reconcile the interests of the various…
As policy makers launch a plethora of initiatives to cushion the short-term effects of the pandemic and stimulate economic recovery, the TransferAllianz points to the potential of academic research for kickstarting longer-term economic upsurge through innovation. It proposes 5 measures to further promote the transfer of research results into novel…
BERLIN, 28 August 2020 – Aignostics, a spin-off from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) pioneering computational pathology for pharmaceutical research and diagnostics, has announced today the closing of a €5 M seed round funding. Boehringer Ingelheim Venture Fund (BIVF) led the round, with participation…
BERLIN, Germany, August 6, 2020 -- T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, announced today the closing of a €66 M Series A round of financing. The round was led by Versant Ventures and RA Capital Management, with significant…
Results further corroborate the potential of the company’s MKK4 inhibitor to combat liver disease by restoring the liver’s natural, almost unlimited capacity to regenerate itself. In various in-vivo models, the candidate led to the inhibition of apoptosis and triggered anti-steatotic effects. Moreover, three intravenous administrations of the…
Previously, she was with international law firms based in Rome and Milan, Italy, focusing on intellectual property (IP) law. Cristina studied in Naples at the Federico II University and specialized in IP while in Rome. She also cooperated with the International Law Department of the Federico II University as an independent researcher.
